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Premature ovarian failure (POF) is genetically heterogeneous and manifests as hypergonadotropic hypogonadism either as part of a
syndrome or in isolation.We studied two unrelated consanguineous families with daughters exhibiting primary amenorrhea, short stat-
ure, and a 46,XX karyotype. A combination of SNP arrays, comparative genomic hybridization arrays, and whole-exome sequencing
analyses identified homozygous pathogenic variants in MCM9, a gene implicated in homologous recombination and repair of
double-stranded DNA breaks. In one family, theMCM9 c.1732þ2T>C variant alters a splice donor site, resulting in abnormal alternative
splicing and truncated forms of MCM9 that are unable to be recruited to sites of DNA damage. In the second family, MCM9 c.394C>T
(p.Arg132*) results in a predicted loss of functional MCM9. Repair of chromosome breaks was impaired in lymphocytes from affected,
but not unaffected, females in both families, consistent with MCM9 function in homologous recombination. Autosomal-recessive var-
iants inMCM9 cause a genomic-instability syndrome associated with hypergonadotropic hypogonadism and short stature. Preferential
sensitivity of germline meiosis to MCM9 functional deficiency and compromised DNA repair in the somatic component most likely
account for the ovarian failure and short stature.In premature ovarian failure (POF [MIM 311360]), ovaries
cease to produce mature oocytes prior to 40 years of
age.1,2 The condition is characterized by secondary amen-
orrhea, infertility, hypoestrogenism, and elevated serum
levels of follicle-stimulating hormone (FSH). POF is herita-
ble in up to 30% of individuals.3 Pathogenesis of POF in-
cludes abnormalities of the X chromosome or autosomes
and can also be due to autoimmune, infectious, and envi-
ronmental causes.1,2 For a subset of idiopathic cases, a
genetic basis has been shown, and FMR1 (MIM 309550),
FSHR (MIM 136435), PMM2 (MIM 601785), GALT (MIM
606999), AIRE (MIM 607358), and FOXL2 (MIM 605597)
are the only genes currently recommended for clinical
genetic testing.2,4 In cases of short stature and POF,
karyotype is usually performed for ruling out 45,X or
Turner syndrome, and subsequent evaluation depends on
the clinical presentation. Several genomic-instability disor-
ders are known to associate with short stature and hypogo-
nadism and include Bloom syndrome (MIM 210900),5
Fanconi anemia (MIM 227650),6 ataxia telangiectasia
(MIM 208900),7 and Nijmegen breakage syndrome (MIM
251260).8
We separately investigated two independent consan-
guineous Turkish families of Kurdish ethnicity for primary
amenorrhea (the absence of menstruation) in their daugh-
ters (Figures 1A and 1B). Peripheral-blood samples were
obtained from affected (AII-4, AII-6, and BII-1) and unaf-
fected (AI-1, AI-2, AII-1, AII-2, AII-3, AII-5, AII-7, BI-1,
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In family A, the parents are first-degree cousins. The
mother (AI-2) entered menarche at 15 years of age, re-
ported normal pubertal development, and continues to
have regular menstrual periods (26- to 28-day menstrual
cycles) at 49 years of age. She had no difficulties becoming
pregnant and is currently 150 cm tall and weighs 68 kg.
She gave birth to six girls and one boy. Two of her daugh-
ters (AII-4 and AII-6) were initially clinically evaluated for
a Turner-like phenotype of primary amenorrhea and short
stature (Figure 1A). All clinical investigations are described
in Table S1 (available online). In summary, the affected
daughters presented with hypergonadotropic primary
amenorrhea, short stature, low weight, and a normal
46,XX karyotype. Estradiol levels were low, whereas lutei-
nizing hormone (LH) and FSH levels were high. Prolactin
levels were normal. Ovaries were not identified on pelvic
ultrasound, and the uteri were infantile. Both individuals
are currently regularly menstruating on combined estro-
gen-progestin replacement therapy and are achieving
appropriate bone ages, pubic-hair stages, and Tanner stages
of breast development. There is no known family history
of anemia, blood dyscrasias, photosensitivity, immunode-
ficiency, or malignancies. Three unaffected sisters (AII-2,
AII-3, and AII-5), aged 22–26 years, all entered menarche
between the ages of 12 and 13 years and are currently expe-
riencing regular menstrual cycles. The youngest sister,omens Research Institute, University of Pittsburgh, Pittsburgh, PA 15213,
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Figure 1. Pathogenic Homozygous Recessive Variants in MCM9 Were Identified in Two Consanguineous Kurdish Families from
Turkey
(A and B) TheMCM9 genotype is provided below each individual. WT denotes the wild-type allele. MT (formutation) indicates either (A)
MCM9 c.1732þ2T>C or (B)MCM9 c. 394C>T. PCR amplification was completed with the KAPA HiFi HotStart PCR Kit with dNTPs (Kapa
Biosystems) according to the manufacturer’s instructions (primers for A are 50-TCTAGGAGGTCCCGAGATGG-30 and 50-CAAAGGCA
GAGTGATTGCCG-30; primers for B are 50-GCCTGAGAGGCAAGTGAATTTAG-30 and 50-TACCTAAAACCAAGGATGTGGGA-30). PCR
products were sequenced at Beckman Coulter Genomics. Results were analyzed with Sequencher (Gene Codes Corporation). Sample
chromatograms are shown (50 to 30 direction in A; 30 to 50 direction in B). Arrows point to the nucleotide peak of interest. Samples utilized
for whole-exome sequencing (WES) are indicated by an asterisk.
(C)MCM9 is encoded on chr6: 119,252,903–119,134,612 (UCSCGenome Browser hg19). TheMCM9 c.1732þ2T>C splice variant lies in
the splice donor site of exon 9 (red arrow). The c.394C>Tmutation lies near the 50 end of exon 2 (blue arrow). Exons are indicated as full
boxes (black). Alternative splice forms of MCM9 either include or exclude exon 11 (white). Introns are indicated as lines.
(D) MCM9 consists of an N-terminal DNA binding domain and AAAþ core domain. The c.1732þ2T>C mutation is predicted to disrupt
normal splicing after amino acid 577. The c.394C>Tmutation causes insertion of a stop codon in the place of an arginine at position 132
(p.Arg132*). This most likely results in a truncated protein if one is formed. The yellow box represents the arginine finger domain (RF),
the pink box represents the Walker A motif (WA), and the deep green box represents the Walker B motif (WB).AII-7, presented with developmental delay and short stat-
ure, but not ovarian failure. She was excluded from further
genetic analyses because of abnormal de novo chromo-
somal microarray findings (Figure S1), which most likely
explain her phenotype.
An unrelated family B has a 16-year-old girl (BII-1;
Figure 1B) with primary amenorrhea, short stature, and aThe Americanlack of breast development. Her medical history is other-
wise unremarkable. Clinical investigations are summarized
in Table S1. She was found to haveminimal breast develop-
ment, stage III (P3) pubic hair, and stage II axillary-hair
development. She had short stature, low weight, and a
bone age of 11 years (Table S1). Pelvic ultrasonography re-
vealed an infantile uterus and no visible ovaries. Her basalJournal of Human Genetics 95, 754–762, December 4, 2014 755
estradiol level was low, whereas LH and FSH levels were
elevated. Prolactin levels measured in the normal range.
She has a normal 46,XX female karyotype. She has regular
menstrual bleeding with combined estrogen-progestin
replacement therapy. Hormone replacement therapy led
to increased height, weight, and breast development. The
proband’s mother (BI-2) is currently 39 years of age. She
exhibited signs of thelarche at 10 years of age and had
normal first menarche at 13 years of age. She continues
to cycle normally. She is 157.5 cm tall and weighs 61 kg.
The 13-year-old unaffected sister (BII-3) had a normal first
menarche at 12 years of age and has had regular menstrual
cycles. Her height is 150.1 cm (1.0 SD), and her weight is
37.4 kg (1.1 SD). Additionally, the proband has two
healthy brothers (BII-2 and BII-4) who have no known
medical problems.
To identify the genetic cause of primary amenorrhea in
family A, we performed DNA copy-number analysis and
homozygosity mapping in two affected individuals (AII-4
and AII-6) and four unaffected female siblings (AII-2,
AII-3, AII-5, and AII-7) by using a 180K comparative
genomic hybridization (CGH) and SNP oligonucleotide
array (SurePrint G3 ISCA design CGHþSNP, Agilent). The
CGHþSNP microarray identified two contiguous regions
of homozygosity on chromosomes 1 and 6: 1p34.3 (chr1:
35,187,876–36,929,988; UCSC Genome Browser hg19)
and 6q21–q22.33 (chr6: 114,543,815–127,262,938; UCSC
Genome Browser hg19). They were shared by the two
affected daughters, but not by unaffected individuals
(Figure S2). These two regions of homozygosity did not
contain genes known to be associated with human ovarian
failure and short stature. We therefore undertook an unbi-
ased whole-exome sequencing (WES) approach to identify
pathogenic variants.
We conducted WES on three unaffected daughters
(AII-2, AII-3, and AII-5), both parents (AII-1 and AII-2),
and two affected siblings (AII-4 and AII-6). Exons and
splice sites were captured with the Agilent SureSelectXT
Human Exon V4þUTRs Kit, and 2 3 100 bp paired-end
WES was performed on an Illumina HiSeq 2500. Quality
metrics for sequencing are shown in Table S2. We prepared
reads for analysis with Cutadapt version 1.2.1 to remove
the adapters and with the FASTX-Toolkit version 0.0.13.2
to trim the first 5 bp at the 50 end of reads. We aligned
data to UCSC Genome Browser hg19 by using Burrows-
Wheeler Aligner version 0.7.3a MEM (maximal exact
match).9,10 Alignment statistics are presented in Tables S2
and S3. Local realignment around insertions and deletions,
recalibration of read base quality, and variant calling
were conducted with Genome Analysis Toolkit (GATK)
version 2.6-5. GATK HaplotypeCaller was used for calling
variants. Variant filtering is described in Table S4.
The number of family members and availability of unaf-
fected siblings enhanced the ability to filter gene variants
that did not match an autosomal-recessive inheritance
model. Three variants in CEP85L (6q22.31, RefSeq acces-
sion number NM_001042475), GEMIN4 (17p13.3, RefSeq756 The American Journal of Human Genetics 95, 754–762, DecembNM_015721), and MCM9 (6q22.31, RefSeq NM_
017696.2) fit the homozygous autosomal-recessive model
(Table S5). CEP85L andMCM9mapped to the homozygos-
ity region shared by affected sisters on chromosome 6
(Figure S2). The CEP85L variant (c. 497A>T [p.Asp166Val])
was previously reported as a SNP (rs9489444) with an allele
frequency of 3% and is not conserved across species.
We eliminated CEP85L as a likely cause of the observed
phenotype.
The MCM9 c.1732þ2T>C variant (chr6: 119,149,088,
UCSC Genome Browser hg19) changes an intron 9 splice
donor site that is conserved at the nucleotide level across
species including mouse, Xenopus, and zebrafish (Figures
1C and 1D). This variant is not present in either the NHLBI
Exome Sequencing Project Exome Variant Server or
1000 Genomes. The MCM9 c.1732þ2T>C variant was
confirmed by Sanger Sequencing (Figure 1A). A control
population of women who were of European descent and
who had at least one live birth was recruited at Magee-
Womens Hospital. Written informed consent and samples
were obtained and subsequently deidentified at the time of
recruitment. The study was approved by the institutional
review board of the University of Pittsburgh. The MCM9
c.1732þ2T>C mutation was not present in the 200 fertile
women from this cohort.
We examined the effect of the c.1732þ2T>C mutation
on MCM9 RNA alternative splicing products. mRNAs
from Epstein-Barr-virus-transformed lymphoblastoid cell
lines were generated from an unrelated control individual
(wild-type), the unaffected mother (AI-2, heterozygous),
and one affected daughter (AII-6, homozygous). RNA was
isolated with Trizol (Invitrogen) and was reverse tran-
scribed to cDNA with the SuperScript III First-Strand Syn-
thesis Kit (Invitrogen). Using the KAPA HiFi HotStart PCR
Kit with dNTPs (Kapa Biosystems) and primers to amplify
exons 7–12 (c.1151_1996), we expected to observe two
previously reported wild-type products: an 846 bp product
and a 700 bp product resulting from exon 11 skipping11
(Figure 2A; Figures S3B, S3C, and S4A). Indeed, we
observed these two bands in the control individual
(Figure 2B, left), and Sanger sequencing confirmed the ex-
pected exon order (Figures 2A and 2B; Figure S3B). In the
heterozygous individual, we observed the 846 bp product,
a faint 700 bp product, and three additional products,
including two faint bands at 954 bp and 499 bp and a
stronger band at 646 bp (Figures 2A and 2B). We were
not able to detect either wild-type product in AII-6, the
affected individual homozygous for the MCM9 variant.
Instead, we observed in this individual the three alterna-
tive bands (Figure 2B), which sequencing revealed to be
abnormal splicing products. Using sequencing, we deter-
mined that the 954 bp band was composed of exons 8
and 9 plus 108 bp of downstream intronic sequence
spliced onto exon 10 (Figure S3A). This intronic region
ends at a cryptic splice site and is predicted to encode an
additional 29 amino acids followed by a premature stop
codon (Figure S4B), suggesting that truncated MCM9er 4, 2014
Figure 2. MCM9 c.1732þ2T>C Results in
Abnormal Alternative Splicing and Pre-
vents MCM9 Foci Formation at Sites of
DNA Damage
(A) Schematic of primer design to detect
splicing aberrations and band sizes of
each product analyzed.Wild-type products
are predicted to produce an 846 bp frag-
ment and a 700 bp fragment resulting
from a known alternative splice variant
lacking exon 11. The 954 bp fragment is
an abnormal splicing product that con-
tains 108 bp of intron 9 and is predicted
to introduce a premature stop codon. The
646 bp fragment is an abnormal splicing
product that has a deletion of exon 9,
and the smaller, 499 bp fragment lacks
both exons 9 and 11.
(B) Representative gel image of DNA
products fractionated on agarose gel after
PCR amplification of cDNA derived
from RNA of lymphoblastoid cell lines
from an unrelated wild-type control indi-
vidual, a heterozygous mutation carrier
(AI-2), and an affected homozygous muta-
tion carrier (AII-6). Primers used (shown
in A) were 50-GATCTACTAGTGCAGGTCT
GACG-30 (c.1151 forward) and 50-GCA
CACTCTGATTCTGTAACCTTT-30 (c.1996
reverse). Wild-type control cells and the
heterozygous carrier (AI-2) showed both
the 846 bp and the 700 bp expected iso-
forms. The abnormal splicing variants
induced by the c.1732T>C mutation were
found in the heterozygous mother (AI-2)
and the homozygous affected daughter
(AII-6). Sanger sequencing verified the
abnormal splicing products (Figure S3).
(C) Human embryonic kidney 293T cells
were seeded onto 12 cm2 glass coverslips
coated in poly-L-lysine and cultured under
standard conditions. Transient transfec-
tion of either wild-type MCM9-GFP or
altered MCM9-GFP (c.1732þ2T>C) into
293T cells was performed with Lipofect-
amine 2000 (Invitrogen) according to
the manufacturer’s directions, and DNA
damage was induced by cell exposure to
300 nM mitomycin C (MMC) for 6 hr the
following day. Coverslips were rinsed twice
in PBS, fixed with 3% paraformaldehyde
for 15 min, and incubated in PBS with
20% SDS and 10% Triton X-100 for
15 min. Coverslips were mounted with
Fluoroshield þ DAPI (Sigma) and imaged
with an Olympus Fluoview 500 or
Olympus Provis AX70 confocal microscope. Nuclei were counterstained with DAPI (blue). Foci formed in 293T cells expressing wild-
type MCM9, but not in cells expressing altered MCM9. Representative confocal images taken with a 403 objective are shown.
Scale bars represent 25 mm.lacking the winged helix domain and a unique C-terminal
extension might be produced (RefSeq NP_060166.2).
The 646 bp fragment was a result of abnormal splicing
that skipped exon 9 (Figures S3C and S4C) and is pre-
dicted to delete 68 amino acids. Exon 9 encodes a
portion of MCM9 that is homologous to the sensor 2
domain of the archaeal MCM ATPase domain (Fig-
ure 1D). The sensor 2 domain binds the gamma phosphateThe Americanof ATP and facilitates ATP binding within the active
site.12,13 The 499 bp fragment resulted from alternative
splicing that skipped both exons 9 and 11 (Figures S3B
and S3C). Our results show that MCM9 c.1732þ2T>C
causes abnormal splicing products predicted to disrupt
MCM9 function.
MCM9-containing complexes are known to form foci
at sites of DNA damage.14 To determine whether theJournal of Human Genetics 95, 754–762, December 4, 2014 757
c.1732þ2T>C mutation affects the ability of MCM9
to form foci at sites of DNA damage, we generated
an MCM9-GFP cDNA construct lacking exon 9
(c.1732þ2T>C). We cloned human wild-type MCM9 into
pEGFPC2 (Clontech) in frame with the N-terminal
GFP tag by using XhoI and SalI. pEGFPC2-MCM9
c.1732þ2T>C was generated by QuikChange (Agilent),
which introduced an SphI site for screening. Human
embryonic kidney 293T cells were transfected with
either wild-type MCM9-GFP or altered MCM9-GFP
(c.1732þ2T>C), treated with 300 nM mitomycin C
(MMC) for 6 hr, and prepared for imaging of GFP signal.
GFP foci were counted in 15 cells per experiment. In
damaged cells expressing wild-type MCM9-GFP, GFP accu-
mulation was primarily nuclear—an average of 205 3 (SD)
nuclear GFP foci per cell formed at sites of DNA damage
(Figure 2C, top). In MMC-exposed cells expressing altered
MCM9-GFP, GFP signal was localized to the nucleus, but
foci could not be found at sites of DNA damage
(Figure 2C, bottom). These studies indicate that the
MCM9 c.1732þ2T>C pathogenic variant, lacking exon 9,
inhibits MCM9 from being recruited to sites of DNA
damage.
In family B, we conducted WES on the unaffected
daughter (BII-3), both parents (BI-1 and BI-2), and the
affected daughter (BII-1) by using the same methodology
as described for family A. After variant filtration, there re-
mained 11 variants that fit the homozygous autosomal-
recessive model (Table S5). Of these 11, only the MCM9
variant (c.394C>T [p.Arg132*]) was not present in either
the NHLBI Exome Variant Server or 1000 Genomes (Fig-
ures 1C and 1D). The variant was confirmed by Sanger
Sequencing (Figure 1B, bottom) and was absent in 200
fertile women. This alteration changes a highly conserved
residue to a premature stop codon, presumably resulting in
loss of functional protein.
During gametogenesis, MCM9 is critical for homologous
recombination (HR) in the repair of DNA double-stranded
breaks (DSBs) and stabilization of broken or stalled DNA
replication forks.14–19 Mcm9-deficient mice have gonadal
failure, and fibroblasts from these mice show hypersensi-
tivity to agents that induce DSBs and DNA crosslinks
(i.e., ionizing radiation and MMC), resulting in a higher
number of broken chromosomes, a hallmark of genomic
instability.19 We assayed DNA-repair capabilities of lym-
phocytes derived from a single unrelated control individ-
ual, unaffected individuals (AII-2, BI-2, and BII-3;
Figure 3A), and affected individuals (AII-4, AII-6, and
BII-1; Figure 3B and 3C) as previously described.20
Within-family comparisons suggested a trend where we
observed significantly more chromosomal breaks in cells
from affected individuals from either family than in cells
from the control individual (Figures 3D and 3E). This trend
was more apparent as MMC concentrations increased.
Treatment with 50 nM MMC induced significant numbers
of chromosomal breaks in cells homozygous for the
c.394C>T mutation from BII-1, but not in cells from the758 The American Journal of Human Genetics 95, 754–762, Decembunrelated control individual (p¼ 6.933 105) or heterozy-
gous parent BI-2 (p ¼ 2.69 3 105; Figure 3E). Treatment
with 150 nM MMC revealed significantly more chromo-
somal breaks in cells from individuals homozygous
for the c.1732þ2T>C and c.394C>T mutations (AII-4,
AII-6, or BII-1) than in cells from the unrelated control in-
dividual (p ¼ 2.6 3 107, p ¼ 1.6 3 1014, and p ¼ 3.58 3
108, respectively) or heterozygous carriers (AII-4 versus
AII-2, p ¼ 2.6 3 107; AII-6 versus AII-2, p ¼ 5.4 3 1014;
BII-1 versus BI-2, p ¼ 3.24 3 108; Figures 3D and 3E).
Treatment with 300 nM MMC revealed more chromo-
somal breaks in cells from affected individuals of either
family than in cells from the control individual (AII-4
versus control, p ¼ 7.5 3 108; AII-6 versus control, p ¼
1.63 107; BII-1 versus control, p ¼ 6.9 3 105) or hetero-
zygous family members (AII-4 versus AII-2, p ¼ 7.63 108;
AII-6 versus AII-2, p ¼ 1.5 3 107; BII-1 versus BI-2, p ¼
5.5 3 107; BII-1 versus BII-3, p ¼ 1.2 3 106; Figures 3D
and 3E). Whenwe compared cells of the affected daughters
across both families, BII-1 (c.394C>T) appeared to be more
sensitive to chromosomal breakage at 50 nM (average
breaks per cell ¼ 1.6 5 0.9) than AII-4 (c.1732þ2T>C;
average breaks per cell ¼ 0.6 5 0.5; p ¼ 0.001) or AII-6
(c.1732þ2T>C; average breaks per cell ¼ 0.8 5 0.5;
p ¼ 0.00039). AII-4 and AII-6 had significantly more
breaks then BII-1 at 150 nM (10.5 5 2.1 [AII-4], 8.1 5
2.3 [AII-6], and 4.0 5 1.1 [BII-1]; AII-4 versus BII-1, p ¼
7.5 3 106; AII-6 versus BII-1, p ¼ 4.96 3 108). At the
highest concentration of MMC, BII-1 (average breaks per
cell ¼ 23.5 5 6.6) had significantly more breaks per
cell on average than AII-6 (average breaks per cell ¼
14.79 5 9.23; p ¼ 0.0051), but not AII-4 (average breaks
per cell ¼ 24.1 5 4.0; p ¼ 0.81). Overall, c.394C>T
appeared to have a statistically greater effect than
c.1732þ2T>C on DNA-damage repair in cells treated
with 50 nM MMC. At higher MMC concentrations, repair
appeared to be equally impaired in cells from homozygous
carriers of either MCM9 mutation. In summary, homozy-
gous carriers of the MCM9 variants (c.394C>T and
c.1732þ2T>C) failed to repair DNA damage as effectively
as heterozygous carriers or wild-type individuals. Analysis
of WES data from affected sisters in either family did
not reveal pathogenic variants in genes known to be asso-
ciated with chromosomal instability and/or ovarian failure
(Table S7).
The contribution of single Mendelian genes to idio-
pathic POF is low, as shown by studies on SF1 (MIM
601516) and FOXL2mutations.21–24 To determine whether
MCM9 variants underlie idiopathic POF, we investigated
the prevalence of MCM9 mutations in a cohort of 109
idiopathic-POF-affected women (98 European, 6 Hispanic,
3 Indian, 1 African American, 1 of mixed descent) who
were recruited at Magee-Womens Hospital. Informed
written consent and samples were obtained at the time
of recruitment. The study was approved by the institu-
tional review board of the University of Pittsburgh. We
amplified MCM9 exons with the KAPA HiFi HotStart PCRer 4, 2014
Figure 3. Mutations in Human MCM9
Impair the Repair of MMC-Induced Chro-
mosomal Breaks
Homozygous MCM9 mutations c.1732þ
2T>C and c.394C>T associate with an
increased rate of chromosomal breakage.
Peripheral lymphocytes were stimulated
with phytohaemagglutinin and cultured
in the presence of MMC. In brief, cells
were cultured in the presence of MMC
at a concentration of 0, 50, 150, or
300 nM. Cells were harvested after 72 hr
of incubation at 37C. At least ten meta-
phase spreads per sample were evaluated
for chromosome aberrations and breaks
(Table S6).
(A–C) Representative figures of metaphase
spreads from (A) wild-type cells, (B) cells
with homozygous c.1732þ2T>C, and (C)
cells with homozygous c.394C>T are
shown after treatment with 300 nM
MMC. Compared to wild-type cells, homo-
zygous mutant cells showed extensive
chromosome damage with numerous
breaks, nonhomologous exchanges, chro-
matid deletions, complex aberrations,
and acentric fragments (arrows).
(D and E) The mean numbers of chromo-
somal breaks per cell were quantified for
cells from (D) family A (with the
c.1732þ2T>C mutation) and (E) family B
(with the c.394C>T mutation). Bar graphs
show the mean observed number of breaks
per cell (5SD) for each MMC concentra-
tion. At least ten metaphase cells were
studied for affected family members
(AII-4, AII-6, and BII-1), unaffected family
members (AII-2, BII-3, and BI-2), and a
healthy fertile unrelated control female.
Single-factor ANOVAwas utilized for deter-
mining the effect of drug concentration on
each cell line. Two-tailed t tests assuming
unequal variance were used for comparing
two cell lines at a single drug concentra-
tion. ***p< 0.001. Abbreviations are as fol-
lows: MT, mutant; and WT, wild-type.Kit (Kapa Biosystems) according to the manufacturer’s
instructions (primers are provided in Table S8). PCR prod-
ucts were sequenced and analyzed with Sequencher (Gene
Codes Corporation). Among 109 individuals, we identified
eight MCM9 variants (Tables S9 and S10). All of the vari-
ants except one, c.1533C>A (p.Tyr511*), were previously
reported as SNPs. All reported SNPs are benign except for
one, rs200078427 (c.686T>G [p.Val229Gly]), which is pre-
dicted to be probably damaging. We suspect that these
SNPs do not account for the POF phenotype because of
heterozygosity. Our data suggest that the prevalence of
biallelic pathogenic MCM9 variants is low in women
with idiopathic POF.
We combined homozygosity mapping and WES in two
unrelated consanguineous families to identify recessive
pathogenic variants in MCM9. Individuals homozygous
for the MCM9 c.1732þ2T>C and c.394C>T pathogenic
variants shared a Turner-like phenotype characterized by
ovarian insufficiency, short stature, low weight, andThe Americangenomic instability in somatic cells exposed to MMC. We
also showed that cells containing the c.1732þ2T>C and
c.394C>T variants were impaired in their ability to repair
DNA damage, most likely as a result of the inability of
MCM9 to be recruited to sites of DNA damage. Minichro-
mosome maintenance proteins MCM2–MCM7 have been
implicated in DNA-replication elongation and prereplica-
tion-complex formation.25 MCM8 and MCM9 are two of
the last discovered members of the minichromosome
maintenance protein homologs and, by association with
other MCMs, were initially implicated in DNA replica-
tion.15 Unexpectedly, Mcm8- and Mcm9-deficient mice
show a phenotype (infertility and small gonads) primarily
restricted to the germline.19 In addition, somatic cells
exhibit growth defects and chromosomal instability.19
The phenotype of the three affected individuals from two
independent families is very similar to what has been
described in mouse knockouts. MCM8 and MCM9 are reg-
ulators of germ cell survival, are rapidly induced andJournal of Human Genetics 95, 754–762, December 4, 2014 759
recruited to sites of DNA damage, coregulate each other’s
stability, and promote RAD51 recruitment to the chro-
matin.18,19 The mechanisms of their action, induction,
and regulation in homologous recombination remain
poorly understood.
In the germline, the MCM8-MCM9 complex is most
likely required for the resolution of DSBs that occur during
HR between homologous chromosomes in pachytene of
meiosis I. Failure to resolve breaks will lead to oocyte death
and thus very small or absent ovaries in women homozy-
gous for these mutations. A number of mouse mutants
lacking genes involved in meiosis and DNA repair, such
as Dmc1, Msh5, Stag3, and Syce1, lose oocytes rapidly in
part because of their inability to process DSBs.26–29 Indeed,
mutations in DMC1, MSH5, STAG3, and SYCE1 have been
identified in women with POF28,30,31 and underscore the
genetic heterogeneity of POF. DSB genes, including a SNP
inMCM8 (rs16991615), have been implicated in the onset
of menopause by genome-wide association studies
(GWASs).32–37 However, no association has been identified
between menopause and MCM9, including in GWASs.32
The close physical interdependence of MCM8 and
MCM9 shows the importance of this pathway in a spec-
trum of ovarian functions from gonadal development to
menopause.
Genomic-instability syndromes, such as Fanconi ane-
mia,6 can associate with short stature, hypogonadism,
and multiple endocrine dysfunctions.38 The mechanism
of how genomic instability contributes to endocrinopa-
thies has not been elucidated and is most likely linked to
complex regulatory networks in the hypothalamic-pitui-
tary-endocrine axes of the body.38 Heterozygous sisters
and mothers have had unremarkable medical histories to
date, but future follow-up examinations and phenotyping
of additional individuals with MCM9 variants will be of
great importance for understanding their predisposition
to other disorders, including endocrine dysfunction and
cancer.Supplemental Data
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